EN
TR
Laboratory findings in Coronavirus Disease 2019 (COVID-19)
Abstract
Coronavirus disease pandemic is a public health threat that affects the whole world. Most coronavirus infections are mild in humans. Severe acute respiratory syndrome coronavirus-2 causes coronavirus disease (COVID-19) and coronavirus pneumonia. Many results in coronavirus disease have been obtained in the studies conducted so far. Rapid and effective diagnosis of coronavirus disease is vital. Thus; infected people can be isolated earlier and the spread of the disease can be stopped, and treatment of patients in need of treatment can be started immediately. In this review; the classification of patients, laboratory findings and the causes and results of these findings are mentioned.
It is thought that; this review could help clinicians and researchers for diagnosis, classification, treatment and prognosis of coronavirus disease. In addition, it is also thought that; this review helps to find out a biomarker that could be used in conjunction with computed tomography results for rapid and accurate diagnosis and classification of coronavirus disease.
Keywords
Kaynakça
- 1. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020; 323(13):1239–1242. doi:10.1001/jama.2020.2648.
- 2. Richman DD, Whitley RJ, Hayden FG (eds): Clinical Virology, 4th ed. Washington: ASM Press, 2016.
- 3. Drosten C, Gunther S, Preiser W, van der Werf S, Brodt HR, Becker S, Rabenau H, Panning M, Kolesnikova L, Fouchier RA, Berger A, Burguière AM, Cinatl J, Eickmann M, Escriou N, Grywna K, Kramme S, Manuguerra JC, Müller S, Rickerts V, Stürmer M, Vieth S, Klenk HD, Osterhaus AD, Schmitz H, Doerr HW. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003; 348: 1967–76. doi:10.1056/NEJMoa030747.
- 4. WHO. Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003. Dec 31, 2003. (https://www.who.int/csr/sars/country/table2004_04_21/en/)
- 5. de Groot RJ, Baker SC, Baric RS, Brown CS, Drosten C, Enjuanes L, Fouchier RA, Galiano M, Gorbalenya AE, Memish ZA, Perlman S, Poon LL, Snijder EJ, Stephens GM, Woo PC, Zaki AM, Zambon M, Ziebuhr J. Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group. J Virol. 2013 Jul; 87(14):7790-92. doi:10.1128/JVI.01244-13.
- 6. Xu X, Chen P, Wang J, Feng J, Zhou H, Li X, Zhong W, Hao P. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci. 2020; 63, 457–460. doi:10.1007/s11427-020-1637-5.
- 7. Tanaka T, Narazaki M, Kishimoto T. Immunotherapeutic implications of IL-6 blockade for cytokine storm. Immunotherapy. 2016; (8)8:959–70. doi:10.2217/imt-2016-0020.
- 8. Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol. 2014; 6(10):a016295 doi:10.1101/cshperspect.a016295.
Ayrıntılar
Birincil Dil
İngilizce
Konular
Sağlık Kurumları Yönetimi
Bölüm
Derleme
Yayımlanma Tarihi
21 Temmuz 2020
Gönderilme Tarihi
15 Haziran 2020
Kabul Tarihi
7 Temmuz 2020
Yayımlandığı Sayı
Yıl 2020 Cilt: 42 Sayı: 2
AMA
1.Yavuz H, Aydın H. Laboratory findings in Coronavirus Disease 2019 (COVID-19). CMJ. 2020;42(2):198-202. doi:10.7197/cmj.vi.752920